{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:47:06Z","timestamp":1786978026143,"version":"build-2736575974"},"reference-count":104,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82572070"],"award-info":[{"award-number":["82572070"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J cachexia sarcopenia muscle"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune disorders characterized by chronic muscle inflammation and significant extramuscular involvement. A substantial proportion of patients exhibit refractory or relapsing disease despite conventional immunosuppressive therapies, necessitating the development of novel targeted treatments. Recent immunological advances have identified novel therapeutic targets\u2014including B cells, T cells, cytokines and intracellular signalling pathways\u2014paving the way for personalized treatment. Targeted therapies represent promising new approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This comprehensive review synthesizes current evidence on targeted therapies for IIM. We systematically searched PubMed, the Cochrane Library and Google Scholar for studies published before September 2025, including randomized controlled trials, retrospective and observational studies, meta\u2010analyses and case reports. We synthesized evidence on the efficacy and safety of various targeted treatments across IIM subtypes and complications, highlighting recent advances and future directions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Targeted therapies are revolutionizing IIM management. B\u2010cell\u2010targeted therapies constitute a relatively established modality. Rituximab has become a cornerstone therapy for refractory disease, as supported by high\u2010level evidence. Modulation of T\u2010cell costimulation with abatacept benefits specific subtypes. JAK inhibitors show remarkable efficacy, particularly for cutaneous manifestations and interstitial lung disease. Cytokine inhibitors, proteasome inhibitors and low\u2010dose IL\u20102 also show benefits across various IIM subtypes and complications. Novel mechanisms are emerging, including Fc receptor antagonism (efgartigimod) to reduce pathogenic IgG and advanced cellular therapies such as CAR\u2010T\u2010cell therapy and bispecific T\u2010cell engagers (BiTEs), which have induced sustained remission in severe refractory cases. The heterogeneous treatment responses observed between and within IIM subtypes present a central challenge, largely stemming from their diverse underlying immunopathogenic mechanisms. The primary safety concern remains infection risk, necessitating individualized benefit\u2013risk assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The targeted therapy landscape in IIM is rapidly expanding, enabling more precise and effective management. These strategies show significant promise in improving outcomes for patients with refractory disease. Future efforts should focus on optimizing treatment selection through biomarker discovery, conducting larger randomized trials to strengthen the evidence base, and managing long\u2010term safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jcsm.70143","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T23:53:39Z","timestamp":1765410819000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeted Therapy for Idiopathic Inflammatory Myopathy"],"prefix":"10.1002","volume":"16","author":[{"given":"Ruijie","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology West China Hospital, Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology West China Hospital, Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibing","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology West China Hospital, Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8197-9585","authenticated-orcid":false,"given":"Geng","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology West China Hospital, Sichuan University  Chengdu Sichuan China"},{"name":"Department of General Practice, General Practice Medical Center West China Hospital, Sichuan University  Chengdu Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"e_1_2_20_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01033-0"},{"key":"e_1_2_20_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00321-x"},{"key":"e_1_2_20_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew213"},{"key":"e_1_2_20_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00359-9"},{"key":"e_1_2_20_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker138"},{"key":"e_1_2_20_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03310-z"},{"key":"e_1_2_20_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key450"},{"key":"e_1_2_20_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03353-2"},{"key":"e_1_2_20_10_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0544"},{"key":"e_1_2_20_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae307"},{"key":"e_1_2_20_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2018-002168"},{"key":"e_1_2_20_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac438"},{"key":"e_1_2_20_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051609"},{"key":"e_1_2_20_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14016"},{"key":"e_1_2_20_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000591"},{"key":"e_1_2_20_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1568338"},{"key":"e_1_2_20_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581323"},{"key":"e_1_2_20_19_1","article-title":"Efficacy of Obinutuzumab in two Rituximab Refractory Cases of Idiopathic Inflammatory Myopathies With Severe Interstitial Lung Disease","author":"St\u00fctz A. N.","year":"2025","journal-title":"Annals of the Rheumatic Diseases"},{"key":"e_1_2_20_20_1","first-page":"4197","article-title":"Experience on the Use of Obinutuzumab off Label in Patients with Refractory Idiopathic Inflammatory Myopathy","volume":"76","author":"Ilic I.","year":"2024","journal-title":"Arthritis & Rheumatology"},{"key":"e_1_2_20_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221756"},{"key":"e_1_2_20_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2012.04.006"},{"key":"e_1_2_20_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1177721"},{"key":"e_1_2_20_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.04.060"},{"key":"e_1_2_20_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead281"},{"key":"e_1_2_20_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead330"},{"key":"e_1_2_20_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00023-5"},{"key":"e_1_2_20_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"e_1_2_20_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.8753"},{"key":"e_1_2_20_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.09.009"},{"key":"e_1_2_20_31_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315990121"},{"key":"e_1_2_20_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42933"},{"key":"e_1_2_20_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03718-3"},{"key":"e_1_2_20_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00091-8"},{"key":"e_1_2_20_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2408786"},{"key":"e_1_2_20_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42450"},{"key":"e_1_2_20_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12732"},{"issue":"4","key":"e_1_2_20_38_1","first-page":"593","article-title":"Direct Suppression of Autoaggressive CD8+ T Cells With CD80\/86 Blockade in CD8+ T Cell\u2010Mediated Polymyositis Models of Mice","volume":"35","author":"Hasegawa H.","year":"2017","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_20_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211751"},{"key":"e_1_2_20_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.43066"},{"issue":"2","key":"e_1_2_20_41_1","first-page":"377","article-title":"Efficacy and Safety of Abatacept for Interstitial Lung Disease Associated With Antisynthetase Syndrome: A Case Series","volume":"42","author":"Xia N.","year":"2024","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_20_42_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4073879"},{"issue":"10","key":"e_1_2_20_43_1","first-page":"2080","article-title":"Alemtuzumab (Campath\u20101H) for Treatment of Refractory Polymyositis","volume":"35","author":"Thompson B.","year":"2008","journal-title":"Journal of Rheumatology"},{"key":"e_1_2_20_44_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-92-3-365"},{"key":"e_1_2_20_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22477"},{"key":"e_1_2_20_46_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100947"},{"key":"e_1_2_20_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.10.010"},{"key":"e_1_2_20_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02164-5"},{"key":"e_1_2_20_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-023-00941-5"},{"key":"e_1_2_20_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken074"},{"key":"e_1_2_20_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077974"},{"key":"e_1_2_20_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.4744"},{"issue":"2","key":"e_1_2_20_53_1","first-page":"129","article-title":"Basic Cancer Chemotherapy: Experimental Models\u2014Strategy","volume":"1","author":"Mulder J. H.","year":"1978","journal-title":"Cancer Clinical Trials"},{"key":"e_1_2_20_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf388"},{"key":"e_1_2_20_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003599"},{"key":"e_1_2_20_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14712"},{"key":"e_1_2_20_57_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.635654"},{"key":"e_1_2_20_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001235"},{"key":"e_1_2_20_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1497168"},{"key":"e_1_2_20_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa906"},{"key":"e_1_2_20_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11493"},{"key":"e_1_2_20_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.08.007"},{"key":"e_1_2_20_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34465"},{"key":"e_1_2_20_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202857"},{"issue":"6","key":"e_1_2_20_65_1","first-page":"904","article-title":"Interleukin\u20101 Receptor Antagonist for Refractory Anti\u2010MDA5 Clinically Amyopathic Dermatomyopathy","volume":"33","author":"Groh M.","year":"2015","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_20_66_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220213"},{"key":"e_1_2_20_67_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000581"},{"key":"e_1_2_20_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead298"},{"key":"e_1_2_20_69_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"e_1_2_20_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447182"},{"key":"e_1_2_20_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03547-2"},{"key":"e_1_2_20_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead404"},{"key":"e_1_2_20_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41602"},{"key":"e_1_2_20_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045"},{"key":"e_1_2_20_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03170-z"},{"key":"e_1_2_20_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005651"},{"key":"e_1_2_20_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.025"},{"key":"e_1_2_20_78_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.962585"},{"key":"e_1_2_20_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf225"},{"key":"e_1_2_20_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05551-2"},{"key":"e_1_2_20_81_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1568338"},{"key":"e_1_2_20_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003837"},{"key":"e_1_2_20_83_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.7500"},{"key":"e_1_2_20_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1412997"},{"key":"e_1_2_20_85_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.4940"},{"key":"e_1_2_20_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy105"},{"key":"e_1_2_20_87_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1382728"},{"key":"e_1_2_20_88_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1043680"},{"key":"e_1_2_20_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202249851"},{"key":"e_1_2_20_90_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216246"},{"key":"e_1_2_20_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105912"},{"key":"e_1_2_20_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00301-3"},{"key":"e_1_2_20_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00421-8"},{"key":"e_1_2_20_94_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.757099"},{"key":"e_1_2_20_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103186"},{"key":"e_1_2_20_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2025.01.005"},{"key":"e_1_2_20_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.08.2209"},{"key":"e_1_2_20_98_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/monpb6"},{"key":"e_1_2_20_99_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen\u20102023\u2010003238"},{"key":"e_1_2_20_100_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard\u20102022\u2010223541"},{"key":"e_1_2_20_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1990.tb03242.x"},{"key":"e_1_2_20_102_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2653-4"},{"key":"e_1_2_20_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22198"},{"key":"e_1_2_20_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01017-7"},{"key":"e_1_2_20_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22388"}],"container-title":["Journal of Cachexia, Sarcopenia and Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcsm.70143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcsm.70143","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcsm.70143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T08:42:00Z","timestamp":1772959320000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcsm.70143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/jcsm.70143"],"URL":"https:\/\/doi.org\/10.1002\/jcsm.70143","archive":["Portico"],"relation":{},"ISSN":["2190-5991","2190-6009"],"issn-type":[{"value":"2190-5991","type":"print"},{"value":"2190-6009","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70143"}}